Stephanie Davis
Stock Analyst at Barclays
(1.15)
# 3,542
Out of 4,761 analysts
103
Total ratings
33.33%
Success rate
-15.22%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Overweight | $42 → $50 | $42.21 | +18.46% | 2 | Feb 19, 2025 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $168 → $175 | $172.24 | +1.60% | 4 | Jan 31, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $5.78 | -13.49% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $72.37 | +3.63% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.70 | -9.09% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.81 | +24.74% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $10.43 | +82.17% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $241.43 | +20.12% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $18.61 | +28.96% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $127.06 | +4.67% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $39.72 | +46.02% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $3.01 | -0.17% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $0.72 | +4.60% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5.5 → $5 | $6.93 | -27.85% | 10 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $249.85 | -0.34% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $28.22 | +2.76% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $11.51 | +195.40% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $23.20 | +46.55% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $225.79 | +3.19% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $5.23 | +225.05% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $108.60 | -30.02% | 5 | Jun 7, 2022 |
Waystar Holding
Feb 19, 2025
Maintains: Overweight
Price Target: $42 → $50
Current: $42.21
Upside: +18.46%
Quest Diagnostics
Jan 31, 2025
Maintains: Equal-Weight
Price Target: $168 → $175
Current: $172.24
Upside: +1.60%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $5.78
Upside: -13.49%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $72.37
Upside: +3.63%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.70
Upside: -9.09%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.81
Upside: +24.74%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $10.43
Upside: +82.17%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $241.43
Upside: +20.12%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $18.61
Upside: +28.96%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $127.06
Upside: +4.67%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $39.72
Upside: +46.02%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.01
Upside: -0.17%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $0.72
Upside: +4.60%
Oct 9, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $5
Current: $6.93
Upside: -27.85%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $249.85
Upside: -0.34%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $28.22
Upside: +2.76%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $11.51
Upside: +195.40%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $23.20
Upside: +46.55%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $225.79
Upside: +3.19%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $5.23
Upside: +225.05%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $108.60
Upside: -30.02%